CRO Medpace (MEDP) Files $150M IPO

Medpace Holdings (NASDAQ: MEDP) filed a $150 million IPO with the SEC. The company plans to list on the NASDAQ under the symbol 'MEDP'.

The offering is being led by Jefferies, Credit Suisse, UBS and Wells Fargo.

Medpace is a scientifically-driven, global full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services for drug, biologic, and device programs. Medpace’s physician-led, high-science, and disciplined operating approach leverages regulatory and therapeutic expertise to accelerate the global development of safe and effective medical therapeutics across all major areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, and neuroscience. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,300 people worldwide with operations in 35 countries.

For the Successor year ended December 31, 2015, the company generated total net service revenue of $320.1 million and Adjusted EBITDA of $101.2 million, representing net service revenue and Adjusted EBITDA compound annual growth rates, or CAGRs, of 21.7% and 26.2%, respectively, since 2012.

You May Also Be Interested In

• Parabilis Medicines closes $770.5 million IPO and concurrent private placement
• GOWell Technology and Inflection Point file amended merger documents
• Vivos Therapeutics plans rights offering to raise capital